Page last updated: 2024-12-05

resorcinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Resorcinol, also known as 1,3-benzenediol or m-dihydroxybenzene, is a white crystalline organic compound with the formula C6H4(OH)2. It is a dihydric phenol, with two hydroxyl groups attached to a benzene ring. Resorcinol is a common intermediate in the synthesis of other organic compounds, including pharmaceuticals, dyes, and resins. It is also used as an antiseptic, antifungal, and anti-inflammatory agent. Resorcinol is studied for its potential therapeutic applications in conditions such as psoriasis, eczema, and acne. It is also investigated for its ability to inhibit the growth of cancer cells. The compound is also used in the production of a variety of industrial products, including adhesives, coatings, and photographic developers.'

resorcinol: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7951 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

resorcinol : A benzenediol that is benzene dihydroxylated at positions 1 and 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5054
CHEMBL ID24147
CHEBI ID27810
SCHEMBL ID15515
MeSH IDM0098657

Synonyms (217)

Synonym
BIDD:ER0285
AC-14363
LS-13122
chembl24147 ,
phenol derivative, 3
bdbm26189
1,3-dihydroxybenzene, xii
benzene, m-dihydroxy-
nako tgg
nsc1571
c.i. oxidation base 31
developer o
developer r
phenol, m-hydroxy-
.alpha.-resorcinol
m-dioxybenzene
pelagol rs
c.i. developer 4
wln: qr cq
fouramine rs
m-hydroxyphenol
resorcine, technical
fourrine ew
developer rs
dihydroxybenzol
c.i. 76505
m-benzenediol
fourrine 79
nsc-1571
benzene,3-dihydroxy-
m-dihydroxybenzene
3-hydroxycyclohexadien-1-one
pelagol grey rs
durafur developer g
3-hydroxyphenol
resorzin
1,3-dihydroxybenzol
CHEBI:27810 ,
DIVK1C_000041
KBIO1_000041
resorcin (jan)
resorcin (tn)
D00133
resorcinol (usp)
einecs 203-585-2
rcra waste no. u201
resorcine
sulforcin
acnomel
un2876
brn 0906905
caswell no. 723
epa pesticide chemical code 071401
resorcinolum
rezamid
ai3-03996
SPECTRUM_000173
rcra waste number u201
nci-c05970
nsc 1571
benzene, 1,3-dihydroxy-
ccris 4052
hsdb 722
fema no. 3589
benzene-1,3-diol
IDI1_000041
SPECTRUM5_001152
benzene,1,3-dihydroxy resorcinol
inchi=1/c6h6o2/c7-5-2-1-3-6(8)4-5/h1-4,7-8
NCGC00091501-01
1,3-benzenediol
108-46-3
C01751
m-hydroquinone
resorcin
1,3-dihydroxybenzene
resorcinol
rco ,
resorcinol, bioxtra, >=99%
resorcinol, >=98%, fg
resorcinol, acs reagent, >=99.0%
NCGC00091501-03
NCGC00091501-02
KBIOSS_000653
KBIO2_003221
KBIO3_001810
KBIO2_005789
KBIOGR_001399
KBIO2_000653
SPECTRUM4_000990
NINDS_000041
SPBIO_001379
SPECTRUM2_001310
SPECTRUM3_000895
NCIOPEN2_003867
SPECTRUM1500527
resorcinol, reagentplus(r), 99%
HMS2092G07
c.i.-76505
resorcinum
resorcinol [un2876] [poison]
BMSE000415
HMS500C03
R0008
HMS1920P06
AKOS000119813
A801880
NCGC00091501-04
NCGC00091501-05
tox21_202417
NCGC00259966-01
NCGC00253918-01
tox21_300140
pharmakon1600-01500527
nsc-757310
nsc757310
cas-108-46-3
tox21_111140
dtxsid2021238 ,
dtxcid601238
26982-54-7
CCG-39248
FT-0674352
FT-0674353
unii-yul4lo94hk
resorcinol [usp]
4-06-00-05658 (beilstein handbook reference)
yul4lo94hk ,
ec 203-585-2
FT-0606668
resorcinol [who-dd]
resorcin [jan]
resorcinol [iarc]
resorcinol [usp monograph]
fluorescein impurity a [ep impurity]
fluorescein sodium impurity a [ep impurity]
hexylresorcinol impurity b [ep impurity]
resorcinol [hsdb]
resorcinol [inci]
resorcinol [mart.]
resorcinum [hpus]
resorcinol [fhfi]
resorcinol [vandf]
resorcinol [ep monograph]
resorcinol [usp-rs]
resorcinol [mi]
BP-21158
SCHEMBL15515
4E49
NCGC00091501-06
3AQT
tox21_111140_1
1,3-benzene diol
3-hydroxy-phenol
benzen-1,3-diol
3-hydroxy phenol
1,3-dihyroxybenzene
Q-201666
rezamid (salt/mix)
rodol rs
acnomel (salt/mix)
eskamel (salt/mix)
sulforcin (salt/mix)
un 2876
HY-B0907
AB00052085_03
mfcd00002269
resorcinol, acs
F1908-0097
resorcinol, tested according to ph.eur.
sr-05000002092
SR-05000002092-1
resorcinol, united states pharmacopeia (usp) reference standard
resorcinol, saj first grade, >=98.0%
resorcinol, jis special grade, >=99.0%
resorcinol, certified reference material, tracecert(r)
resorcinol, european pharmacopoeia (ep) reference standard
hymecromone impurity a, european pharmacopoeia (ep) reference standard
resorcinol, reagent grade, 98%
resorcinol, pharmaceutical secondary standard; certified reference material
resorcinol, p.a., 99.0-100.5%
resorcinol, lr, >=99%
resorcinol (1,3-dihydroxybenzene)
resorcinol 10 microg/ml in methanol
m-hydroxy-phenol
fema 3589
resorcinol, 8ci
1,3-dihydroxy-benzene
rezorsine
rs 11l
reso
m-phenylenediol
rs 11h
SBI-0051505.P003
DB11085
1,3-benzenediol; 1,3-dihydroxybenzene
Q408865
S4579
m-dihydroxybenzene,(s)
resorcinol, crystalline powder, usp
resorcinol, reagent
resorcinol, flake, technical
BRD-K74190368-001-02-7
EN300-19643
STL185604
remazol
1,3-dihydroxybenzene (resorcinol)
resorcinol (mart.)
resorcinol (usp-rs)
resorcinol (ep monograph)
resorcinol (usp monograph)
fluorescein impurity a (ep impurity)
hexylresorcinol impurity b (ep impurity)
nako-tgg
resorcinol (iarc)
durafor developer g
Z104474576

Research Excerpts

Overview

Resorcinol is a harmful, irritant, methemoglobin-forming and hemolytic substance. It is a suspected endocrine disruptor that affects thyroid function by inhibiting thyroxin peroxidase.

ExcerptReferenceRelevance
"Resorcinol is a harmful, irritant, methemoglobin-forming and hemolytic substance."( [Resorcinol - determination method in the workplace air].
Jeżewska, A; Kondej, D, 2022
)
2.35
"Resorcinol is a suspected endocrine disruptor that affects thyroid function by inhibiting thyroxin peroxidase. "( Environmental and occupational exposure to resorcinol in Finland.
Hartonen, M; Porras, SP; Santonen, T; Tornaeus, J; Tuomi, T; Ylinen, K, 2018
)
2.19
"Resorcinol is an effective inhibitor of oscillations both in MA oscillators and in IMA oscillators."( Experimental and mechanistic investigation of an iodomalonic acid-based Briggs-Rauscher oscillator and its perturbations by resorcinol.
Cervellati, R; Furrow, SD; Greco, E, 2010
)
1.29
"Resorcinol is a pharmaceutical agent used topically in dermatological treatments for acne, eczema, psoriasis and related skin conditions. "( A case report of fatal oral ingestion of resorcinol.
Aydin, SA; Bulut, M; Fedakar, R; Turkmen, N, 2006
)
2.04
"Resorcinol is a simple aromatic chemical (1,3-benzenediol) that has found widespread use, particularly as a coupler in hair dyes. "( The skin sensitization potential of resorcinol: experience with the local lymph node assay.
Basketter, DA; Jowsey, IR; Sanders, D, 2007
)
2.06

Effects

ExcerptReferenceRelevance
"Resorcinol has various uses; for example in the manufacture of rubber products and in wood adhesives, flame retardants, UV stabilizers, and dyes."( Environmental and occupational exposure to resorcinol in Finland.
Hartonen, M; Porras, SP; Santonen, T; Tornaeus, J; Tuomi, T; Ylinen, K, 2018
)
1.46

Actions

Resorcinol was degraded slower and supports higher antibiotic titers than either catechol or hydroquinone. Its potency to inhibit TPO was profoundly lower than that of PTU or MMI.

ExcerptReferenceRelevance
"Resorcinol was degraded slower and supports higher antibiotic titers than either catechol or hydroquinone."( Simultaneous removal of dihydroxybenzenes and toxicity reduction by Penicillium chrysogenum var. halophenolicum under saline conditions.
Ferreira-Guedes, S; Leitão, AL, 2018
)
1.2
"Resorcinol's potency to inhibit TPO was profoundly lower than that of PTU or MMI."( A comparison of potency differences among thyroid peroxidase (TPO) inhibitors to induce developmental toxicity and other thyroid gland-linked toxicities in humans and rats.
Motonaga, K; Odawara, K; Ota, M; Saito, S; Welsch, F, 2016
)
1.16

Toxicity

Microcalorimetric technique based on heat-output measurement, direct microorganism counting and enzymatic activity determination, have been explored to evaluate the toxic effects of diphenol species. Resorcinol caused reversible adverse effects on the human thyroid gland (TG) manifested as hypothyroidism.

ExcerptReferenceRelevance
" It could be very hazardous if taken orally and there are limited reports on its toxic effects in human."( The oral toxicity of resorcinol during pregnancy: a case report.
Cetin, M; Demirel, Y; Demirkoprulu, N; Duran, B; Gurelik, B; Gursoy, S, 2004
)
0.64
"A microcalorimetric technique based on bacterial heat-output was explored to evaluate the toxic effect of different diphenol species on the growth of Escherichia coli (E."( A microcalorimetric method for studying the toxic effect of different diphenol species on the growth of Escherichia coli.
Bramanti, E; Chen, H; Choi, MM; Djak, A; Tian, L; Wang, F; Wang, Y; Yao, J, 2007
)
0.34
"The potential adverse effects of resorcinol, delivered via drinking water at 0, 120, 360, 1000, and 3000 mg/L (palatability limit), were assessed in a regulatory guideline compliant two-generation reproduction study in Crl:CD(SD) rats."( Two-generation reproductive toxicity study of resorcinol administered via drinking water to Crl:CD(SD) Rats.
Lawrence, WB; Nemec, MD; Welsch, F,
)
0.67
"Medical case reports published in the 20th century over the course of several decades show that resorcinol caused reversible adverse effects on the human thyroid gland (TG) manifested as hypothyroidism."( Routes and modes of administration of resorcinol and their relationship to potential manifestations of thyroid gland toxicity in animals and man.
Welsch, F,
)
0.62
"Microcalorimetric technique based on heat-output measurement, direct microorganism counting and enzymatic activity determination, have been explored to evaluate the toxic effects of diphenol species (catechol, resorcinol, and hydroquinone) on soil microbial activity."( Study on the toxic effects of diphenol compounds on soil microbial activity by a combination of methods.
Bramanti, E; Chen, H; Choi, MM; Wang, F; Yao, J; Zaray, G, 2009
)
0.54
"Although phenolic compounds are intensively studied for their toxic effects on the environment, the toxicity of catechol, resorcinol and hydroquinone mixtures are still not well understood because most previous bioassays are conducted solely using single compound based on acute tests."( Toxicity of three phenolic compounds and their mixtures on the gram-positive bacteria Bacillus subtilis in the aquatic environment.
Chen, H; Chen, K; Choi, MM; Wang, F; Yao, J; Zaray, G; Zhou, Y; Zhuang, R, 2010
)
0.57
" As results of toxicity tests, TCS was found to be most strongly toxic for green algae [e."( Ecotoxicity and screening level ecotoxicological risk assessment of five antimicrobial agents: triclosan, triclocarban, resorcinol, phenoxyethanol and p-thymol.
Kagota, K; Kameda, Y; Kimura, K; Morita, J; Nakada, N; Tamura, I; Tatarazako, N; Yamamoto, H; Yasuda, Y; Yoneda, S, 2013
)
0.6

Pharmacokinetics

ExcerptReferenceRelevance
" Repeated dosing for 30 days with maximum tolerated daily doses of 100 mg/kg did not alter pharmacokinetic parameters, nor did it cause overt toxic signs or adverse reactions."( Pharmacokinetics of resorcinol in the rat.
Doughty, D; Merker, PC; Nacht, S; Yeung, D, 1982
)
0.59

Bioavailability

ExcerptReferenceRelevance
"The Cosmetics Europe Skin Bioavailability and Metabolism Task Force aims to improve the measurement and prediction of the bioavailability of topically-exposed compounds for risk assessment."( Comparison of protocols for measuring cosmetic ingredient distribution in human and pig skin.
Cubberley, R; Duplan, H; Eilstein, J; Gerstel, D; Grégoire, S; Hewitt, N; Jacques-Jamin, C; Klaric, M; Rothe, H; Schepky, A, 2016
)
0.43
"The aim of this paper was to compare the in vitro dissolution and in vivo bioavailability of three solubility enhancement technologies for β-lapachone (LPC), a poorly water soluble compound with extremely high crystallization propensity."( Oral bioavailability enhancement of β-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion.
Chen, H; Chen, Y; Chen, Z; Liu, C; Liu, Z; Pui, Y; Qian, F, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Repeated dosing for 30 days with maximum tolerated daily doses of 100 mg/kg did not alter pharmacokinetic parameters, nor did it cause overt toxic signs or adverse reactions."( Pharmacokinetics of resorcinol in the rat.
Doughty, D; Merker, PC; Nacht, S; Yeung, D, 1982
)
0.59
" Those reports neither quantify exposure levels nor demonstrate dose-response relationships or rule out confounding by the multiple other chemicals present in water supplies, by bacterial contamination of water, or by nutritional factors."( Toxicology review and risk assessment of resorcinol: thyroid effects.
Bechtel, DH; Delzell, ES; Lynch, BS, 2002
)
0.58
" The most advanced candidates are now in Phase 2 clinical trials and defining the therapeutic window, dosing schedule, and indication are the primary challenges for these potential first-in-class inhibitors."( Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
Depew, KM; Fritz, CC; Porter, JR, 2010
)
0.36
" The Taguchi experimental design was applied to study the effect of such parameters as the initial component concentrations (C(0,i)) of two solutes (aniline and catechol or aniline and resorcinol) in the solution, temperature (T), adsorbent dosage (m) and contact time (t)."( Adsorptive removal of aniline by granular activated carbon from aqueous solutions with catechol and resorcinol.
Mishrab, IM; Srivastava, VC; Suresh, S,
)
0.54
" sieboldii for the first time, and all three compounds showed cytotoxicity against a panel of cancer cell lines and brine shrimps in a dose-response manner."( Cytotoxic and anti-inflammatory resorcinol and alkylbenzoquinone derivatives from the leaves of Ardisia sieboldii.
Halim, MA; Hossain, MA; Ishii, T; Islam, MT; Shahinozzaman, M; Tawata, S, 2019
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (8 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care8

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Daeng Gi Meo Ri Medicinal Herb Hair Color - Black -- 1 KitDaeng Gi Meo RiBeauty & Personal Carebutylene glycol, P-aminophenol, PCA, ceteth-20, cetyl alcohol, citronellol, dioleyl phosphate, behenyl alcohol, lauryl alcohol, disodium EDTA, ethanolamine, geraniol, hexyl cinnamal, hydroxycitronellal, butylphenyl methylpropional, limon- ene, linalool, myristic acid, myristyl alcohol, oleyl alcohol, palmitic acid, palmitic acid, phenacetin, resorcinol, sodium benzoate, stearic acid, stearyl alcohol, stearyl stearate, threonine2024-11-29 10:47:42
Daeng Gi Meo Ri Medicinal Herb Hair Color - Natural Brown -- 1 KitDaeng Gi Meo RiBeauty & Personal Carebutylene glycol, P-aminophenol, PCA, ceteth-20, cetyl alcohol, citronellol, dioleyl phosphate, behenyl alcohol, lauryl alcohol, disodium EDTA, ethanolamine, geraniol, hexyl cinnamal, hydroxycitronellal, butylphenyl methylpropional, limon- ene, linalool, myristic acid, myristyl alcohol, oleyl alcohol, palmitic acid, palmitic acid, phenacetin, resorcinol, sodium benzoate, stearic acid, stearyl alcohol, stearyl stearate, threonine2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4D Golden Chestnut -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 4R Copper Chestnut -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 5D Light Golden Chestnut -- 135 mLHerbatintBeauty & Personal Careethanolamine, etidronic acid, propylene glycol, resorcinol2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 6D Dark Golden Blonde -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 7D Golden Blonde -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42
Herbatint Permanent Hair Color Gel 8D Light Golden Blonde -- 135 mLHerbatintBeauty & Personal Careascorbic acid, ethanolamine, etidronic acid, propylene glycol, resorcinol, sodium sulfite2024-11-29 10:47:42

Roles (2)

RoleDescription
erythropoietin inhibitorAny inhibitor of erythropoietin, a glycoprotein hormone that controls erythropoiesis (red blood cell production).
sensitiserA chemical compound that causes a substantial proportion of exposed people or animals to develop an allergic reaction in normal tissue after repeated exposure to the compound.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzenediol
resorcinolsAny benzenediol in which the two hydroxy groups are meta to one another.
phenolic donorAny phenol that acts as an electron donor.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
thyroid hormone biosynthesis524
resorcinol degradation59
u03B3-resorcylate degradation II411
u03B3-resorcylate degradation I413
alkylnitronates degradation350
superpathway of aromatic compound degradation3349

Protein Targets (62)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.39810.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.18830.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency33.35790.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency30.53750.000221.22318,912.5098AID1259243; AID588515; AID743035; AID743036
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency42.00400.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency44.66840.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency8.90820.000657.913322,387.1992AID1259377
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency10.96400.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency26.50270.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency42.38940.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.01880.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency47.12920.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.37780.000229.305416,493.5996AID743069
caspase-3Homo sapiens (human)Potency42.00400.013326.981070.7614AID1346978
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency50.15660.000627.21521,122.0200AID651741; AID743202
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency13.33590.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency1.00000.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency74.97800.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki7.70000.09003.89507.7000AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki7.70000.09003.89507.7000AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki7.70000.09003.89507.7000AID977610
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)1,072.33330.03403.987110.0000AID1312207; AID1312208; AID411500
Carbonic anhydrase 12Homo sapiens (human)Ki278.25000.00021.10439.9000AID1798641; AID342484
Carbonic anhydrase 1Homo sapiens (human)Ki388.54290.00001.372610.0000AID1238072; AID1798641; AID1803140; AID1803217; AID331291; AID342475
Carbonic anhydrase 2Homo sapiens (human)Ki276.07140.00000.72369.9200AID1238073; AID1798641; AID1803140; AID1803217; AID331292; AID342476
Carbonic anhydrase 3Homo sapiens (human)Ki320.92860.00022.010210.0000AID1798641; AID342477
TyrosinaseHomo sapiens (human)IC50 (µMol)3,000.00000.02304.459310.0000AID1717717
Prolyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)Ki10,200.00005.00007.66679.0000AID1799825
Carbonic anhydrase 4Homo sapiens (human)Ki333.91580.00021.97209.9200AID1798641; AID1803140; AID1803217; AID342478
Carbonic anhydrase 6Homo sapiens (human)Ki308.93330.00011.47109.9200AID1798641; AID1803217; AID342481
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki278.33570.00001.27259.9000AID1798641; AID342479
Carbonic anhydrase 7Homo sapiens (human)Ki323.71430.00021.37379.9000AID1798641; AID342482
Carbonic anhydrase 9Homo sapiens (human)Ki282.69290.00010.78749.9000AID1798641; AID342483
Carbonic anhydraseDicentrarchus labrax (European seabass)Ki6.42002.13005.53339.4100AID607497
Carbonic anhydrase 3Bos taurus (cattle)Ki377.28000.11303.88159.7100AID1803140; AID1803217
Carbonic anhydrase 15Mus musculus (house mouse)Ki385.00000.00091.884610.0000AID331293
Carbonic anhydrase 13Mus musculus (house mouse)Ki282.18570.00021.39749.9000AID1798641; AID342486
Carbonic anhydrase 14Homo sapiens (human)Ki278.47860.00021.50999.9000AID1798641; AID342485
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki278.22140.00001.34129.9700AID1798641; AID342480
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Bacterial regulatory proteins, tetR familyCorynebacterium glutamicum ATCC 13032Kd0.19000.19000.19000.1900AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
procollagen-proline 4-dioxygenase activityProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
iron ion bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
L-ascorbic acid bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Bos taurus (cattle)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
endoplasmic reticulum lumenProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
endoplasmic reticulumProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (145)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1717717Inhibition of human His-tagged tyrosinase expressed in HEK 293 cells using L-DOPA as substrate by MBTH based assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID1312210Activity of mushroom tyrosinase using TBC as substrate assessed as accumulation of p-quinone in presence of H2O2 spectrophotometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID342476Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID266762Effective permeability coefficient in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID395643Activity of Crotalus adamanteus venom PLA2 assessed as 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol hydrolysis at 0.30 uM2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID203473Binding constant against bovine serum albumin1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID266768Membrane permeability, CA(t)/CD(0) in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID342484Inhibition of human carbonic anhydrase 12 catalytic domain by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1312208Inhibition of mushroom tyrosinase using L-dopa as substrate assessed as diphenolase activity by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID1238073Inhibition of human erythrocytes CA2 using 4-nitrophenylacetate as substrate by esterase assay2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
AID1291721Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion by measuring minimal hemolytic dose administered immediately after venom injection measured after 24 hrs (Rvb =5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1238074Competitive inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by Lineweaver-Burk plot analysis2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
AID395646Inhibition of Crotalus adamanteus venom PLA2-induced edema in Swiss mouse at 50 ug, id2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID607497Inhibition of Dicentrarchus labrax CA using 4-nitrophenylacetate substrate by esterase assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds.
AID1238072Inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by esterase assay2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
AID1312215Substrate activity at mushroom tyrosinase assessed as Kcat/Km ratio for monophenolase activity in presence H2O2 by spectrophotometry based Michaelis-Menten plot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID332456Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA1994Journal of natural products, Apr, Volume: 57, Issue:4
Tyrosinase inhibitors from Anacardium occidentale fruits.
AID362542Antibacterial activity against macrolide-resistant Staphylococcus aureus RN4220 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID282835Cytotoxicity against mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID23978Capacity ratio (log k'w)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID332455Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA at 0.8 mM1994Journal of natural products, Apr, Volume: 57, Issue:4
Tyrosinase inhibitors from Anacardium occidentale fruits.
AID40936Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I501982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1312214Substrate activity at mushroom tyrosinase assessed as Kcat for monophenolase activity in presence H2O2 by spectrophotometry based Michaelis-Menten plot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID342482Inhibition of human carbonic anhydrase 7 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID266767Membrane retention in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID266765Effective permeability coefficient in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID266769Membrane retention in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID333444Binding affinity to COX1 in sheep seminal vesicle2004Journal of natural products, Nov, Volume: 67, Issue:11
Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study.
AID1291714Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion by measuring minimal hemolytic dose preincubated with venom for 1 hr followed by administration to mo2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID395642Activity of Crotalus adamanteus venom PLA2 assessed as 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol hydrolysis at 0.15 uM2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID266763Membrane retention in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID362541Antibacterial activity against methicillin-resistant Staphylococcus aureus SA1199B after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID395644Inhibition of Crotalus adamanteus venom PLA2 assessed as effect on 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol hydrolysis at 0.15 uM2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID1291716Lipophilicity, log P of compound2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID342475Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1312213Substrate activity at mushroom tyrosinase assessed as Km for monophenolase activity in presence H2O2 by spectrophotometry based Michaelis-Menten plot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID1291722Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID342479Inhibition of human carbonic anhydrase 5A by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID362543Antibacterial activity against tetracycline-resistant Staphylococcus aureus XU212 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID331292Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID342485Inhibition of human carbonic anhydrase 14 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1312211Inactivation of mushroom tyrosinase using TBC as substrate assessed as reduction in p-quinone accumulation pre-incubated at 0.3 mM for shorter time duration during 0 to 500 secs by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID395645Inhibition of Crotalus adamanteus venom PLA2 assessed as effect on 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol hydrolysis at 0.30 uM2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID23714Partition coefficient (logP)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID1125765Partition coefficient, log P of the compound in methanol-water mixture at 0.25 mg/ml by HPLC analysis2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Polyfluorinated bis-styrylbenzenes as amyloid-β plaque binding ligands.
AID411500Inhibition of mushroom tyrosine kinase assessed as oxidation of 0.25 mM L-3,4-dihydroxyphenylalanine2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
PEG-immobilization of cardol and soluble polymer-supported synthesis of some cardol-coumarin derivatives: preliminary evaluation of their inhibitory activity on mushroom tyrosinase.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID24226Partition coefficient (logP)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID1291717Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.28ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1312216Inactivation of mushroom tyrosinase using TBC as substrate assessed as reduction in p-quinone accumulation pre-incubated at 0.3 mM for longer time duration during 0 to 500 secs by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID23101Acidity of compound was determined1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Acidic epinephrine analogues derived from 1H, 3H-2,1,3-benzothiadiazole 2,2-dioxide and from trifluoromethanesulfonanilide. A new synthesis of 1H,3H-2,1,3-benzothiadiazole 2,2-dioxide.
AID418552Antiradical activity against 2,2'-azobis-amidinopropane-induced linoleic acid peroxidation assessed as ratio of total oxyradical scavenging capacity to Trolox C2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Antioxidant and antiradical activities of resorcinarene tetranitroxides.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID733606Inactivation of tyrosinase (unknown origin) assessed as initial rate of oxygen utilization using 4-methylcatechol substrate at 850 uM by spectrophotometry2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Mechanistic studies of the inactivation of tyrosinase by resorcinol.
AID333439Inhibition of peroxidase activity of COX1 in heep seminal vesicle by TMPD assay2004Journal of natural products, Nov, Volume: 67, Issue:11
Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study.
AID733602Inactivation of tyrosinase (unknown origin) assessed as total oxygen uptake using 4-methylcatechol substrate at 850 uM by spectrophotometry2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Mechanistic studies of the inactivation of tyrosinase by resorcinol.
AID266771Permeability in human skin2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID266770Membrane permeability, CA(t)/CD(0) in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID333442Effect on COX1 activity in sheep seminal vesicle at 5 uM by TMPD peroxidase assay2004Journal of natural products, Nov, Volume: 67, Issue:11
Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study.
AID362545Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 15 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID331293Inhibition of mouse recombinant carbonic anhydrase 15 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID342477Inhibition of human carbonic anhydrase 3 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1291710Protective activity against Daboia russellii venom-induced mortality by measuring venom LD50 in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.28 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID266766Dissociation constant, pKa of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID282834Activity against caspase-mediated apoptosis in mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID733604Inactivation of tyrosinase (unknown origin) assessed as initial rate of oxygen utilization at absorbance 400 nm using 4-methylcatechol substrate at 850 uM by spectrophotometry2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Mechanistic studies of the inactivation of tyrosinase by resorcinol.
AID26261Partition coefficient (logD7.2)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID310932Permeability across human Skin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1291719Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID362544Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 25923 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID342483Inhibition of human carbonic anhydrase 9 catalytic domain by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1312209Substrate activity at mushroom tyrosinase using TBC as substrate assessed as increase in TBC oxidation at 0.05 to 0.50 mM by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID331291Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID1291715Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative t2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1130099Inhibition of human aromatase using androstenedione as substrate assessed as remaining estrone level at 10 uM after 30 mins by LC-MS/MS analysis relative to control2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Inhibitory effect of Rhus verniciflua Stokes extract on human aromatase activity; butin is its major bioactive component.
AID418551Antioxidant activity assessed as [drug]/[DPPH]causing 50% DPPH radical scavenging activity after 5 mins2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Antioxidant and antiradical activities of resorcinarene tetranitroxides.
AID333440Inhibition of cyclooxygenase activity of COX1 in sheep seminal vesicle in presence of 1 mM phenol by cyclooxygenase assay2004Journal of natural products, Nov, Volume: 67, Issue:11
Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study.
AID342480Inhibition of human carbonic anhydrase 5B by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID342486Inhibition of mouse carbonic anhydrase 13 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1449742Selectivity ratio of Ki for recombinant human carbonic anhydrase 2 to Ki for recombinant Malassezia globosa beta-carbonic anhydrase2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID342478Inhibition of human carbonic anhydrase 4 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID333443Inactivation of holo-COX1 in sheep seminal vesicle assessed as drug oxidization at 2.5 to 4 nmol by RP-HPLC in presence of hydrogen peroxide2004Journal of natural products, Nov, Volume: 67, Issue:11
Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study.
AID733600Inactivation of tyrosinase (unknown origin) assessed as decay half-life using 4-methylcatechol substrate at 850 uM by spectrophotometry2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Mechanistic studies of the inactivation of tyrosinase by resorcinol.
AID1449738Inhibition of Malassezia globosa recombinant beta-carbonic anhydrase preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID342481Inhibition of human carbonic anhydrase 6 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID266764Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1616110Inhibition of F1F0-ATP synthase in Escherichia coli relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID23676Partition coefficient (logP)1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Acidic epinephrine analogues derived from 1H, 3H-2,1,3-benzothiadiazole 2,2-dioxide and from trifluoromethanesulfonanilide. A new synthesis of 1H,3H-2,1,3-benzothiadiazole 2,2-dioxide.
AID1291712Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1449741Selectivity ratio of Ki for recombinant human carbonic anhydrase 1 to Ki for recombinant Malassezia globosa beta-carbonic anhydrase2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID362546Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 16 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID25611Dissociation constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID40623Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1312207Inhibition of mushroom tyrosinase using L-tyrosine as substrate assessed as monophenolase activity by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Characterization of the action of tyrosinase on resorcinols.
AID1695183Inhibition of recombinant bovine liver ARGI at 500 uM using L-arginine as substrate incubated for 60 mins by spectroscopic analysis relative to control2020RSC medicinal chemistry, May-01, Volume: 11, Issue:5
Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2012Chemical communications (Cambridge, England), May-28, Volume: 48, Issue:43
Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors.
AID1798641CA Inhibition Assay from Article 10.1016/j.bmc.2008.06.013: \\Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.\\2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1803140Esterase Activity Assay from Article 10.3109/14756366.2011.643303: \\Carbonic anhydrase inhibitors: in vitro inhibition of a isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids.\\2013Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 28, Issue:2
Carbonic anhydrase inhibitors: in vitro inhibition of α isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids.
AID1799825Inhibition Assay from Article : \\Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.\\1986The Journal of biological chemistry, Jun-15, Volume: 261, Issue:17
Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.
AID1803217Esterase Activity Assay from Article 10.3109/14756366.2011.651464: \\Analysis of saponins and phenolic compounds as inhibitors of a-carbonic anhydrase isoenzymes.\\2013Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 28, Issue:2
Analysis of saponins and phenolic compounds as inhibitors of α-carbonic anhydrase isoenzymes.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011PloS one, May-03, Volume: 6, Issue:5
Crystal structures of the transcriptional repressor RolR reveals a novel recognition mechanism between inducer and regulator.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (692)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990213 (30.78)18.7374
1990's73 (10.55)18.2507
2000's138 (19.94)29.6817
2010's220 (31.79)24.3611
2020's48 (6.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.18 (24.57)
Research Supply Index6.60 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index149.73 (26.88)
Search Engine Supply Index2.12 (0.95)

This Compound (79.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.41%)5.53%
Reviews22 (3.00%)6.00%
Case Studies22 (3.00%)4.05%
Observational1 (0.14%)0.25%
Other685 (93.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]